BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Foller S, Oppel-Heuchel H, Fetter I, Winkler Y, Grimm MO. [Adverse events of immune checkpoint inhibitors]. Urologe A 2017;56:486-91. [PMID: 28246759 DOI: 10.1007/s00120-017-0342-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lai F, Ji M, Huang L, Wang Y, Xue N, Du T, Dong K, Yao X, Jin J, Feng Z, Chen X. YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer. Acta Pharmaceutica Sinica B 2022;12:2845-58. [DOI: 10.1016/j.apsb.2022.02.031] [Reference Citation Analysis]
2 Grimm MO, Leucht K, Grünwald V, Foller S. New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. J Clin Med 2020;9:E565. [PMID: 32092974 DOI: 10.3390/jcm9020565] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
3 Shi Y, Lin P, Ho EY, Nock CJ. Nivolumab-associated nausea and vomiting as an immune adverse event. European Journal of Cancer 2017;84:367-9. [DOI: 10.1016/j.ejca.2017.07.029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
4 Vaziri H, Turshudzhyan A, Vecchio E. Immunotherapy-induced Colitis: A Comprehensive Review of Epidemiology, Clinical Presentation, Diagnostic Workup, and Management Plan. J Clin Gastroenterol 2022. [PMID: 35470301 DOI: 10.1097/MCG.0000000000001705] [Reference Citation Analysis]
5 Lin LL, Lin GF, Yang F, Chen XQ. A systematic review and meta-analysis of immune-mediated liver dysfunction in non-small cell lung cancer. Int Immunopharmacol 2020;83:106537. [PMID: 32371246 DOI: 10.1016/j.intimp.2020.106537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Grimm M, Oppel-heuchel H, Foller S. Therapie mit PD-1/PD-L1- und CTLA-4-Immun-Checkpoint-Inhibitoren: Immunvermittelte Nebenwirkungen. Urologe 2018;57:543-51. [DOI: 10.1007/s00120-018-0635-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
7 Tian Y, Abu-sbeih H, Wang Y. Immune Checkpoint Inhibitors-Induced Hepatitis. In: Naing A, Hajjar J, editors. Immunotherapy. Cham: Springer International Publishing; 2018. pp. 159-64. [DOI: 10.1007/978-3-030-02505-2_8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
8 Miller K, Bergmann L, Doehn C, Grünwald V, Gschwend JE, Ivanyi P, Kuczyk MA. [Interdisciplinary recommendations for the treatment of advanced renal cell carcinoma]. Aktuelle Urol 2021. [PMID: 34852368 DOI: 10.1055/a-1579-0562] [Reference Citation Analysis]
9 Suresh K, Naidoo J, Lin CT, Danoff S. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest 2018;154:1416-23. [PMID: 30189190 DOI: 10.1016/j.chest.2018.08.1048] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 18.3] [Reference Citation Analysis]
10 Grimm M, Bex A, De Santis M, Ljungberg B, Catto JW, Rouprêt M, Hussain SA, Bellmunt J, Powles T, Wirth M, Van Poppel H. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology 2019;76:368-80. [DOI: 10.1016/j.eururo.2019.05.041] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
11 Vasiljevic D, Arnold C, Neuman D, Fink K, Popovscaia M, Kvitsaridze I, Nevinny-Stickel M, Glatzer M, Lukas P, Seppi T. Occurrence of pneumonitis following radiotherapy of breast cancer - A prospective study. Strahlenther Onkol 2018;194:520-32. [PMID: 29450591 DOI: 10.1007/s00066-017-1257-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
12 Miller K, Bergmann L, Doehn C, Grünwald V, Gschwend JE, Ivanyi P, Keilholz U, Kuczyk MA. [Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma]. Aktuelle Urol 2020;51:572-81. [PMID: 33027832 DOI: 10.1055/a-1252-1780] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]